BridgeBio Pharma annual shares outstanding
2018
2019
2020
2021
2022
2023
2024
2025
BridgeBio Pharma Shares Outstanding History (BBIO)
BridgeBio Pharma reported 194.8M shares outstanding at the end of fiscal 2025.
View full BridgeBio Pharma company overviewBridgeBio Pharma annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 194.8M | 4.7M | +2.49% |
| 2024 | 2024-12-31 | 190.0M | 15.0M | +8.55% |
| 2023 | 2023-12-31 | 175.1M | 24.5M | +16.24% |
| 2022 | 2022-12-31 | 150.6M | 3.3M | +2.23% |
| 2021 | 2021-12-31 | 147.3M | 24.5M | +19.94% |
| 2020 | 2020-12-31 | 122.8M | −808,898 | −0.65% |
| 2019 | 2019-12-31 | 123.7M | 31.6M | +34.33% |
| 2018 | 2018-12-31 | 92.1M | — | — |
BridgeBio Pharma quarterly shares outstanding
Q4.18
As of May 17, 2019
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 195.3M | 4.1M | +2.16% |
| Q1 2026 | 2026-03-31 | 195.7M | 5.9M | +3.10% |
| Q4 2025 | 2025-12-31 | 194.8M | 4.7M | +2.49% |
| Q3 2025 | 2025-09-30 | 192.6M | 3.6M | +1.93% |
| Q2 2025 | 2025-06-30 | 191.2M | 3.1M | +1.66% |
| Q1 2025 | 2025-03-31 | 189.8M | 2.7M | +1.44% |
| Q4 2024 | 2024-12-31 | 190.0M | 15.0M | +8.55% |
| Q3 2024 | 2024-09-30 | 189.0M | 14.9M | +8.53% |
| Q2 2024 | 2024-06-30 | 188.0M | 26.6M | +16.49% |
| Q1 2024 | 2024-03-31 | 187.1M | 26.7M | +16.63% |
| Q4 2023 | 2023-12-31 | 175.1M | 24.5M | +16.24% |
| Q3 2023 | 2023-09-30 | 174.1M | 24.8M | +16.58% |
| Q2 2023 | 2023-06-30 | 161.4M | 13.2M | +8.89% |
| Q1 2023 | 2023-03-31 | 160.4M | 12.7M | +8.63% |
| Q4 2022 | 2022-12-31 | 150.6M | 3.3M | +2.23% |
| Q3 2022 | 2022-09-30 | 149.4M | 2.3M | +1.55% |
| Q2 2022 | 2022-06-30 | 148.2M | −1.4M | −0.92% |
| Q1 2022 | 2022-03-31 | 147.7M | −1.4M | −0.96% |
| Q4 2021 | 2021-12-31 | 147.3M | 24.5M | +19.94% |
| Q3 2021 | 2021-09-30 | 147.1M | 24.5M | +20.03% |
| Q2 2021 | 2021-06-30 | 149.6M | 27.4M | +22.38% |
| Q1 2021 | 2021-03-31 | 149.1M | 27.8M | +22.87% |
| Q4 2020 | 2020-12-31 | 122.8M | −808,898 | −0.65% |
| Q3 2020 | 2020-09-30 | 122.5M | 5.2M | +4.42% |
| Q2 2020 | 2020-06-30 | 122.3M | 122.3M | — |
| Q1 2020 | 2020-03-31 | 121.4M | 121.4M | — |
| Q4 2019 | 2019-12-31 | 123.7M | 31.6M | +34.33% |
| Q3 2019 | 2019-09-30 | 117.4M | — | — |
| Q2 2019 | 2019-06-30 | 0 | — | — |
| As of May 17, 2019 | 2019-05-17 | 0 | — | — |
| Q4 2018 | 2018-12-31 | 92.1M | — | — |
BridgeBio Pharma shares outstanding trends
Over the last five reported fiscal years, BridgeBio Pharma's shares outstanding moved from 122.8M to 194.8M, a change of 71.9M. The latest reported quarter, Q2 2026, shows 195.3M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BridgeBio Pharma filings at SEC.gov ↗